BPC-157 Dosage: What the Research Actually Used

By Victor Björk

Every dose figure circulating in peptide communities for BPC-157 traces back to rat studies, run almost entirely by a single research group, converted to human equivalents through a body-surface-area formula that was never designed for this purpose. There is no completed Phase II trial. There is no human pharmacokinetic profile. The “200–500 mcg per day” figure that appears on forums and gray-market vendor sites is an extrapolation built on extrapolations, and anyone presenting it as an established dose is telling you something the published literature does not support.

What the evidence hierarchy actually looks like

The honest answer is that the evidence base for BPC-157 dosing in humans is essentially empty. No peer-reviewed publication reports a completed Phase II or Phase III trial evaluating BPC-157 efficacy or dosing in human subjects. A 2025 systematic review in HSS Journal (the musculoskeletal journal of Hospital for Special Surgery) screened the available literature and found 35 preclinical studies and exactly one small retrospective clinical report, in which 7 of 12 patients described pain relief after intraarticular injection. [1] No control group. No blinding. No dose verification. The review’s conclusion was unambiguous: no high-quality clinical evidence base currently exists for BPC-157 in orthopaedic sports medicine.

The preclinical work itself is substantial in volume, and in rodent models the findings are at least internally consistent. A 2026 systematic review in Pharmaceuticals found that BPC-157 consistently demonstrated efficacy across rat studies of tendon, ligament, muscle, and musculoskeletal junction injuries, administered intraperitoneally, intragastrically, via drinking water, and topically. [2] The same review explicitly called for clinical studies, because none of that rodent consistency translates automatically into human dosing guidance.

The PL-10 dead end. One formulation derived from BPC-157 research, developed under the Pliva designation PL-14736, entered early-stage human trials for inflammatory bowel disease. Results were never published in a peer-reviewed journal, leaving the human pharmacodynamic profile entirely uncharacterized. That is the closest the compound has come to rigorous human study, and it went nowhere the scientific community can examine.

The dose range researchers actually used in rats

Because the rodent data is what everything else is built on, it deserves a precise accounting rather than a vague summary.

• Intraperitoneal injection: The most frequently cited protocol in tendon and ligament repair studies uses 10 mcg/kg once daily, in some cases extended across 14 consecutive days post-injury. [2]

• Subcutaneous injection: A 2021 study by Sikiric’s group in Frontiers in Pharmacology used both 10 mcg/kg and 10 ng/kg subcutaneously in a rat model of abdominal compartment syndrome, finding reductions in vascular congestion and hemodynamic disturbances at both doses. [3] That is a four-log dose range producing overlapping efficacy signals in the same model, which should immediately complicate any attempt at a straightforward dose-response extrapolation.

• Oral and intragastric routes: Oral administration has been used in rat ulcer models, but no pharmacokinetic study in any species has measured systemic BPC-157 plasma concentrations following oral dosing. Whether the peptide survives gastric transit and reaches systemic circulation in meaningful quantities has simply not been answered. [4]

Route of administration determines everything about what dose is relevant. A dose that works intraperitoneally in a rat tells you very little about what an oral dose should be in a human, particularly when the oral bioavailability data do not exist.

The body-surface-area conversion problem

The commonly cited human-equivalent range of 200–500 mcg per day derives from applying the Reagan-Shaw et al. (2008) body-surface-area scaling formula to the rat data above. This is a legitimate method for initial dose estimation in drug development, it is used routinely in Phase I trial design to establish a starting dose for first-in-human studies, specifically so that a proper pharmacokinetic study can then determine whether the conversion was anywhere close to accurate.

For BPC-157, that Phase I study never happened, or if it did, the results were never published. [1] The body-surface-area conversion is supposed to be a starting hypothesis, not a final answer. In the peptide community it has become the final answer, which is a category error.

A 2026 narrative review in Pharmaceutics identified the core pharmacokinetic problem directly: BPC-157 has a plasma half-life of under 30 minutes in preclinical models, yet produces biological effects lasting hours to days. [4] That disconnect has not been explained mechanistically, which means dosing interval calculations derived from the half-life alone are almost certainly wrong. The review concluded that BPC-157 has no validated dosing regimen, no completed Phase II trial, and that available clinical data derive from fewer than 30 subjects across three uncontrolled pilot studies with no standardized pharmaceutical preparations.

Bottom line: The “200–500 mcg” figure is a body-surface-area estimate that was never validated by a human pharmacokinetic study. It is a guess dressed up as a protocol.

Mechanism: what has biochemical support

The claimed mechanisms deserve the same scrutiny as the dosing figures, because they are often used to argue that the compound must work in humans on the grounds that the biology is plausible.

What the animal data show: BPC-157 upregulates VEGFR2 and promotes angiogenesis in rat tissue, a finding that appears across multiple Sikiric-group studies using immunohistochemistry with measurable vessel-density increases. The nitric oxide system has also been implicated, with BPC-157 attenuating NOS inhibitor-induced hypertension in rat models, though the receptor-level interaction remains uncharacterized.

What has not been shown: Claims that BPC-157 acts as a growth hormone secretagogue or modulates the GH/IGF-1 axis rest on cell-line observations that have not been confirmed in intact-animal pharmacokinetic studies, let alone in humans. Cell-line findings are useful for generating hypotheses; they are not evidence that a mechanism operates in a living system at physiologically achievable concentrations.

The angiogenesis mechanism also carries a risk that has received almost no attention in the promotional literature. BPC-157 promotes new blood vessel formation via VEGFR2 upregulation, the same pathway that several approved cancer therapies specifically block. Bevacizumab, sunitinib, and sorafenib all target VEGF/VEGFR signaling precisely because angiogenesis feeds tumor growth. Administering a compound that upregulates this pathway in a person with an occult or early-stage malignancy is not a theoretical concern that can be dismissed. No carcinogenicity study of BPC-157 has been published. The preclinical toxicology work has not identified an LD50 at doses up to 10 mg/kg in rats, which is a favorable acute safety signal, but chronic toxicity data beyond 30-day protocols are absent, and acute tolerance says nothing about cancer risk. [4]

BPC-157 against better-studied comparators

The compound’s advocates in sports medicine often frame BPC-157 as an alternative to PRP (platelet-rich plasma) for tendon repair, implying the two are roughly equivalent options with different evidence bases. A 2022 meta-analysis of 17 randomized controlled trials found that PRP injections provided superior pain relief, functional outcomes, and quality of life compared to control interventions for common shoulder diseases in humans. [5] BPC-157 has one small uncontrolled retrospective report. That is not a close call, and framing it as a matter of differing evidence bases obscures how lopsided the comparison actually is.

TB-500, the thymosin beta-4 fragment frequently co-administered with BPC-157 in self-experimentation protocols, shares the overlapping angiogenic and tissue-repair claims and also lacks human RCT data. Stacking two compounds with no validated human dosing does not produce a validated protocol; it produces two unknowns compounded into one.

What would actually change the picture

Independent replication of the Sikiric-group findings by laboratories without institutional ties to that group has not appeared in high-impact peer-reviewed journals. That absence, sustained across decades of published rodent work, is the single most important gap in the current evidence base. The field has had time to replicate these findings and has not done so, which should weigh on anyone treating the preclinical literature as settled.

Any future human dosing study will need plasma pharmacokinetic measurements across multiple routes of administration before the rodent-to-human extrapolations currently in circulation can be validated or discarded. The half-life problem alone, sub-30-minute clearance producing multi-day effects, needs a mechanistic explanation before dosing intervals can be rationally designed. [1]

Until that work exists, the dosing figures in circulation are not evidence-based recommendations. They are the peptide community’s best guesses, applied to an unregulated product sourced primarily from compounding operations with no quality verification, by people who have no way to know whether what they are injecting matches the label. No published study was designed to evaluate that risk profile, because no published study was designed to evaluate it at all.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.

References

1. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.. HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025.

2. Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review.. Pharmaceuticals (Basel, Switzerland), 2026.

3. Stable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats.. Frontiers in pharmacology, 2021.

4. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers.. Pharmaceutics, 2026.

5. Can platelet-rich plasma injections provide better pain relief and functional outcomes in persons with common shoulder diseases: a meta-analysis of randomized controlled trials.. Clinics in shoulder and elbow, 2022.